July 31, 2013

The Food and Drug Administration has approved a Perrigo generic drug for treating dermatitis, the company said Wednesday.

July 29, 2013

U.S.-based drug maker Perrigo Co. will buy Ireland's Elan Corp. for $8.6 billion, the companies said.

July 19, 2013

Perrigo announced the tentative approval for repaglinide tablets, a generic version of Novo Nordisk's Prandin, used to treat Type 2 diabetes.

June 25, 2013

Tyco Integrated Security on Tuesday announced it has teamed up with Perrigo Nutritionals to develop a theft-resistant infant formula container.

June 24, 2013

Perrigo on Monday promoted Emily Hiller to assistant category manager for the category management team at Perrigo Nutritionals in Gordonsville, Va.

June 17, 2013

Perrigo Co. will pay up to $129 million to buy Fera Pharmaceuticals' portfolio of ophthalmic products, Perrigo said.

May 29, 2013

The Food and Drug Administration has approved a generic drug for incontinence made by Perrigo Co., the drug maker said.

May 13, 2013

Perrigo on Monday announced it has kicked off a broad industry marketing and communications campaign to raise awareness for, and consumer confidence in, generic over-the-counter store-brand medications.

May 8, 2013

There is as much as $10 billion in branded pharmaceutical sales that could make the switch from prescription-only to over-the counter in the next five years, suggested Joseph Papa, Perrigo chairman, CEO and president, to analysts on Tuesday.

April 1, 2013

Perrigo Co. has completed its acquisition of a Pennsylvania-based animal health company, the drug maker said.

March 18, 2013

Perrigo announced that it has begun shipments of guaifenesin 600-mg extended-release tablets. It's the first product that is generically equivalent to Reckitt Benckiser's Mucinex 600-mg extended-release tablets.

February 21, 2013

The Generic Pharmaceutical Association re-elected its chairman from last year and appointed a new board of directors for 2013 whose members run from A to Z — as in Amneal to Zydus.

February 5, 2013

The Food and Drug Administration has approved a testosterone gel product made by Perrigo, the drug maker said.

February 4, 2013

Drug maker Perrigo has launched a generic drug for treating problems of the scalp, the company said.

February 4, 2013

Perrigo chairman, CEO and president Joe Papa shared with analysts that private label OTCs are trending strong and that growth will be sustained going forward with the number of projected Rx-to-OTCs on the horizon.

February 1, 2013

Leading private-label supplier Perrigo has acquired pet health company Velcera for $160 million.

January 25, 2013

Perrigo Nutritionals is introducing new packaging that the company said would make providing nutrition to infants more convenient.

January 24, 2013

Perrigo and a subsidiary of K-V Pharmaceutical Co. have launched a new drug for yeast infections in women, the two companies said.

January 22, 2013

Perrigo announced that it has begun shipments of over-the-counter nicotine polacrilex mini lozenge USP, 2 mg (mint flavor) and 4 mg (mint flavor), comparable to GlaxoSmithKline's Nicorette mini lozenge.

January 15, 2013

CVS/pharmacy has decided to stock Tylenol pain reliever in only half of its stores, according to a Reuters report published Monday.

December 28, 2012

Solidifying Perrigo’s leadership position in topical foam-based generic prescription pharmaceuticals, the company announced it has signed a definitive merger agreement and completed the acquisition of Cobrek Pharmaceuticals.

November 28, 2012

The Food and Drug Administration has approved a drug from Perrigo and Cobrek Pharmaceuticals for treating scalp conditions.

November 8, 2012

Business for OTC store brands is expected to boom in the coming year, Perrigo chairman and CEO Joseph Papa told analysts discussing the private-label manufacturer's first quarter results during a conference call Wednesday, even as the growth rate across the entire OTC category slows.

October 16, 2012

Perrigo has received tentative approval from the U.S. Food and Drug Administration for its abbreviated new drug application to market over-the-counter omeprazole and sodium bicarbonate capsules in the 20-mg/1,100-mg strength, the store-brand equivalent to Merck's Zegerid OTC.